Earnings Anticipation: Recent chatter on social media has been buzzing about Royalty Pharma’s upcoming fourth quarter and full-year 2025 financial results, set to be announced on February 11, 2026. Many are eager to see if the company’s raised guidance will hold after a mixed quarterly performance. This has sparked curiosity about their revenue growth trajectory.
Dividend Increase: Another hot topic is the recent dividend hike to $0.235, payable in March. Discussions highlight optimism around this move, with some viewing it as a sign of confidence in sustained cash flow. It’s a point of interest for income-focused investors.
Liquidity Concerns: However, not all conversations are positive, as some have raised flags about liquidity risks, pointing to very low trading volumes. This has led to worries about potential challenges in exiting positions. The debate adds a layer of caution to the narrative.
Note: This discussion summary was generated from an AI condensation of post data.
Royalty Pharma Insider Trading Activity
Royalty Pharma insiders have traded $RPRX stock on the open market 33 times in the past 6 months. Of those trades, 0 have been purchases and 33 have been sales.
Here’s a breakdown of recent trading of $RPRX stock by insiders over the last 6 months:
- GEORGE W. LLOYD (EVP, Investments & CLO) has made 0 purchases and 11 sales selling 355,426 shares for an estimated $13,807,997.
- TERRANCE P. COYNE (EVP & CFO) has made 0 purchases and 12 sales selling 347,922 shares for an estimated $13,534,004.
- MARSHALL URIST (EVP, Research & Investments) has made 0 purchases and 9 sales selling 183,151 shares for an estimated $7,213,665.
- GREGORY NORDEN sold 33,500 shares for an estimated $1,213,748
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Royalty Pharma Revenue
Royalty Pharma had revenues of $609.3M in Q3 2025. This is an increase of 7.9% from the same period in the prior year.
You can track RPRX financials on Quiver Quantitative's RPRX stock page.
Royalty Pharma Hedge Fund Activity
We have seen 296 institutional investors add shares of Royalty Pharma stock to their portfolio, and 186 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 25,441,140 shares (-69.9%) from their portfolio in Q3 2025, for an estimated $897,563,419
- FMR LLC removed 12,371,107 shares (-30.7%) from their portfolio in Q3 2025, for an estimated $436,452,654
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 5,965,633 shares (+99.4%) to their portfolio in Q3 2025, for an estimated $210,467,532
- CAPITAL INTERNATIONAL INVESTORS added 5,332,074 shares (+24.4%) to their portfolio in Q3 2025, for an estimated $188,115,570
- VIKING GLOBAL INVESTORS LP removed 2,597,460 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $91,638,388
- JUPITER ASSET MANAGEMENT LTD removed 2,470,706 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $87,166,507
- MORGAN STANLEY removed 2,440,149 shares (-5.2%) from their portfolio in Q3 2025, for an estimated $86,088,456
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Royalty Pharma Analyst Ratings
Wall Street analysts have issued reports on $RPRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 10/10/2025
- Goldman Sachs issued a "Buy" rating on 09/30/2025
To track analyst ratings and price targets for Royalty Pharma, check out Quiver Quantitative's $RPRX forecast page.
Royalty Pharma Price Targets
Multiple analysts have issued price targets for $RPRX recently. We have seen 3 analysts offer price targets for $RPRX in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Steve Scala from TD Cowen set a target price of $45.0 on 12/11/2025
- Terence Flynn from Morgan Stanley set a target price of $54.0 on 10/10/2025
- Asad Haider from Goldman Sachs set a target price of $42.0 on 09/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
